… Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms
and LC-MS/MS. Curr Pharm Biotechnol 2016, 17, 788–801, doi:10.2174/…

… HiTrap Blue highperformance column and albumin kit and IgG … samples for the LC-MS/MS
analysis and determine the … On the regulatory approval pathway of biosimilar products. …

… glycoproteomic analysis using SEC-LC-MS/MS, analysis of … -drug conjugates (ADCs),
biosimilars, and several protein thera… glucosidase inhibitors that significantly minimize …

… of applicable chemistries, miniaturization of reaction volumes, … for glycan analysis on IgG
Fc fragment by CGE-LIF after IgG … using C18 nano-LC-MS/MS followed by data analysis. (B) …

… Additionally, the rise of biosimilars, due to the expiration of … , and then to a fluorescent
tagged IgG molecule (FITC-IgG). … inherent characteristics and drawbacks for miniaturization are …

… to years, and some mAbs or biosimilars will apply to a large … the quality of a pharmaceutical
product by monitoring process … to help guide the analysis of the manufacturing processes. …

… in LC-MS/MS peptide mapping of the standard NISTmAb immunoglobulin G (IgG)1κ can be
… CZE-MS/MS analysis for characterization of biosimilar candidates of therapeutic antibodies […

… ; (ii) analysis of fundamental process characteristics, and (iii) … precipitation unit initial parameters
(Immunoglobulin G, yield, and … , new membranes and miniaturization has emerged. SUB …

… drug, Avastin, and its biosimilar in pre-clinical … the biosimilar. Structural MS proved to be
an effective technique in the rapid and facile characterization of biosimilarity and in the analysis …

… analysis of glycan isomers from biological samples are needed. Here, we describe the necessary
steps for the analysis of native and permethylated N-glycans using … LC-MS/MS analysis …